Austrian arenaviral vector technology specialist Hookipa Biotech AG (Vienna, Austria) has licenced its TheraT and Vaxwave technologies exclusively to Gilead Sciences Inc. to develop and globally commercialise vaccines against the human immunodeficiency virus (HIV) and the hepatitis B virus (HBV).
PureTech Health plc announced today that its affiliate, Gelesis, has appointed Harry Leider, MD, MBA, former Chief Medical Officer and Group Vice President of Walgreens, as Chief Medical Officer.
https://european-biotechnology.com/wp-content/uploads/2024/04/eb_online_Leiden.jpg303303h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-06-05 15:15:452018-06-05 15:15:45PureTech’s Gelesis Appoints Harry Leider as CMO
The US FDA has accepted a supplemental BLA to Roche’s existing market approval of the new hemophilia A treatment Hemlibra (emicizumab), which could significantly extend the patient group covered by the label.
https://european-biotechnology.com/wp-content/uploads/2024/04/Emicizumab_MoA__2_.png18885529Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-06-05 08:04:252018-06-05 08:04:25Roche set to extend Hemlibra label
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended nine medicines for approval, including two orphan medicines, at its May 2018 meeting.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-06-04 05:57:122018-06-04 05:57:12EMA recommends nine drugs for approval
Despite seemingly insurmountable environmental challenges ahead and the many successes’ flaunted by big biorefinery projects, the wider business community remains stubbornly sceptical about developing business within the bio-based paradigm. Now policymakers are pushing financiers to take a bigger stake in its success. New efforts are underway to drive private investment in bioeconomy ventures.
https://european-biotechnology.com/wp-content/uploads/2024/04/eb_2018_spring_bioeconomy.jpg5631000Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-06-03 05:08:002024-04-02 16:21:21Follow the money – from niche to norm
Sygnature Discovery, thas appointed Dr Bill Marathias as Vice President of Business Development for the US to assist with the company’s international growth plans.
https://european-biotechnology.com/wp-content/uploads/2024/04/Eb_online_appointments_sygnature.JPG700700h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-06-01 15:59:562018-06-01 15:59:56Sygnature Discovery appoints Dr Bill Marathias
Bavarian Nordic A/S today announced the appointment of Henrik Juuel to the position of Executive Vice President and Chief Financial Officer. Mr. Juuel is currently the CFO of Orexo AB.
https://european-biotechnology.com/wp-content/uploads/2024/04/eb_online_appointment_juuel.jpg420420h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-05-31 16:29:422018-05-31 16:29:42Bavarian Nordic to appoint Henrik Juuel as CFO
Brain disease specialist Denali Therapeutics will buy all outstanding shares in British F-Star Gamma Ltd from F-Star instead licencing bispecific antibody candidates that can cross the blood-brain barrier (BBB) co-developed under an agreement dating back to 2016.
Hookipa and Gilead ink US$400m deal
Latest NewsAustrian arenaviral vector technology specialist Hookipa Biotech AG (Vienna, Austria) has licenced its TheraT and Vaxwave technologies exclusively to Gilead Sciences Inc. to develop and globally commercialise vaccines against the human immunodeficiency virus (HIV) and the hepatitis B virus (HBV).
PureTech’s Gelesis Appoints Harry Leider as CMO
AppointmentsPureTech Health plc announced today that its affiliate, Gelesis, has appointed Harry Leider, MD, MBA, former Chief Medical Officer and Group Vice President of Walgreens, as Chief Medical Officer.
Roche set to extend Hemlibra label
Latest NewsThe US FDA has accepted a supplemental BLA to Roche’s existing market approval of the new hemophilia A treatment Hemlibra (emicizumab), which could significantly extend the patient group covered by the label.
Hikma appoints Henriette Nielsen
AppointmentsHikma Pharmaceuticals PLC announces the appointment of Henriette Nielsen to the newly created role of Chief Transformation Officer.
EMA recommends nine drugs for approval
Latest NewsThe European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended nine medicines for approval, including two orphan medicines, at its May 2018 meeting.
Follow the money – from niche to norm
BackgroundDespite seemingly insurmountable environmental challenges ahead and the many successes’ flaunted by big biorefinery projects, the wider business community remains stubbornly sceptical about developing business within the bio-based paradigm. Now policymakers are pushing financiers to take a bigger stake in its success. New efforts are underway to drive private investment in bioeconomy ventures.
Sygnature Discovery appoints Dr Bill Marathias
AppointmentsSygnature Discovery, thas appointed Dr Bill Marathias as Vice President of Business Development for the US to assist with the company’s international growth plans.
New epilepsy target discovered
Latest NewsFrench researchers have found a key driver of chronic epilepsy.
Bavarian Nordic to appoint Henrik Juuel as CFO
AppointmentsBavarian Nordic A/S today announced the appointment of Henrik Juuel to the position of Executive Vice President and Chief Financial Officer. Mr. Juuel is currently the CFO of Orexo AB.
Denali bags F-Star Gamma
Latest NewsBrain disease specialist Denali Therapeutics will buy all outstanding shares in British F-Star Gamma Ltd from F-Star instead licencing bispecific antibody candidates that can cross the blood-brain barrier (BBB) co-developed under an agreement dating back to 2016.